Combating Ovarian Cancer Using Stem Cell-Engineered Off-The-Shelf CAR-iNKT Cells

Research Objective

HSC-engineered allogeneic mesothelin-targeting CAR-iNKT (AlloMCAR-iNKT) cells

Impact

treatment of ovarian cancer

Major Proposed Activities

Milestone 1. Production of the AlloMCAR-iNKT cells
Milestone 2. Characterization of the AlloMCAR-iNKT cells
Milestone 3. Delivery of the new therapeutic candidate

Ovarian cancer (OC) is the leading cause of death among women with gynecological malignancies. In the USA, California is the state with the highest incidences and deaths of ovarian cancer. In 2021, it is estimated that 2,550 women will be diagnosed with OC and 1,640 women will die from this disease at California. Therefore, novel therapies are urgently needed. The proposed project can potentially lead to a novel off-the-shelf cell therapy for ovarian cancer and save lives